Gyre Therapeutics opened lower at $4.20, compared with its previous close of $4.26. In the last trading session, the stock traded between $4.09 and $4.36. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Gyre Therapeutics is now worth
$ 63.98
Resulting in a loss of
$ 36.02 (36.02%)
Invest with $1
Note: Past profits do not guarantee future returns.
Gyre Therapeutics affirmed FY26 sales guidance of $100.5 million to $111.0 million. The reaffirmed range remains unchanged from previous disclosures. The guidance midpoint is below the analyst estimate of $109.5 million.
7 days ago
7Aug
Gyre Therapeutics Latest Results: Sales guidance affirmed at $100.5M-$111M
Gyre Therapeutics maintains its FY2026 sales guidance of $100.500 million to $111.000 million, matching the prior outlook. The projection exceeds the $102.300 million analyst estimate, reflecting steady confidence in the company's revenue drivers and commercial strategy for the fiscal year.
Gyre Therapeutics reported a Q2 net loss of $14.3 million, missing EPS estimates despite beating revenue forecasts. The earnings miss was driven by a 129% surge in R&D expenses, including a $4.8 million milestone payment for F351, and costs associated with the recent Cullgen acquisition.
3mo ago
17Jul
Gyre Therapeutics appoints three new directors to its board
Gyre Therapeutics, Inc. has appointed Yue Xiong, Ph.D., Maxwell Kirkby, and Claire Weston, Ph.D., to its Board of Directors, effective August 1, 2026. The appointments expand the board's expertise in science, clinical development, and cross-border biopharmaceutical operations. Xiong and Kirkby join as Class I and II directors, respectively, while Weston becomes a Class III director.
